SCHEMBL256709

SCHEMBL256709

CC/C=C/c1ccc2c(c1)OCO2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.66
ATM Q13315 1/20 0.66
CYP19A1 P11511 2/20 0.57
TRPM8 Q7Z2W7 1/20 0.56
ALDH1A1 P00352 4/20 0.55
HSD17B10 Q99714 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
NPC1 O15118 1/20 0.53
MTOR P42345 1/20 0.53
RAB9A P51151 1/20 0.53
VCP P55072 1/20 0.53
KDM4E B2RXH2 3/20 0.53
GABRA1 P14867 2/20 0.53
GABRB2 P47870 2/20 0.53
PGR P06401 1/20 0.53
AR P10275 1/20 0.53
MAOA P21397 1/20 0.53
SLC6A2 P23975 1/20 0.53
PDE4A P27815 1/20 0.53
KDR P35968 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9149832 1.00 CYP3A4 (0.66) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL2056144 0.89 KDM4E (0.54) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL11011121 0.86 CYP3A4 (0.62) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL11011119 0.86 CYP3A4 (0.62) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL2360927 0.83 CYP3A4 (0.46) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL406395 0.83 ALDH1A1 (0.66) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL19472000 0.82 CYP19A1 (0.78) CYP3A4ATMCYP19A1ALDH1A1HSD17B10
SCHEMBL19500874 0.82 CYP19A1 (0.78) CYP3A4ATMCYP19A1ALDH1A1HSD17B10
SCHEMBL2005021 0.82 CYP3A4 (0.61) CYP3A4ATMCYP19A1TRPM8ALDH1A1
SCHEMBL22187024 0.82 CYP3A4 (0.61) CYP3A4ATMCYP19A1TRPM8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160304485-A1 SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-20 US disclosed
WO-2012028578-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER CROPSCIENCE AG (DE) 2012-03-08 WO disclosed
US-20110166141-A1 CATHEPSIN S INHIBITORS DCB-USA, LLC (US) 2011-07-07 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
US-5475024-A Useful in treating liver disease EISAI CO., LTD. (JP) 1995-12-12 US disclosed
US-5292901-A Benzodioxole derivatives EISAI CO., LTD. (JP) 1994-03-08 US disclosed
EP-0281098-B1 BENZODIOXOLE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME, AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS Eisai Co., Ltd. (JP) 1992-11-25 EP disclosed
US-5110956-A Liver disorders EISAI CO., LTD. (JP) 1992-05-05 US disclosed
EP-0281098-A1 Benzodioxole derivatives, compositions comprising the same, and the use of the same for the manufacture of medicaments Eisai Co., Ltd. (JP) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304485-A1 SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF MCL1, BCL2L1, BCL2L11 CYP3A4 4502/4885ATM 2469/4885CYP19A1 4389/4885
US-20110166141-A1 CATHEPSIN S INHIBITORS CTSS, CTSV, CTSB CYP3A4 2657/4885ATM 4418/4885CYP19A1 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.